Literature DB >> 10479534

The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6.

E C Breen1, M van der Meijden, W Cumberland, T Kishimoto, R Detels, O Martínez-Maza.   

Abstract

B cell hyperactivation accompanies HIV infection and is believed to contribute to the increased incidence of B cell lymphoma in persons with AIDS. To examine B cell activation which precedes the development of AIDS-associated lymphoma, we measured levels of two B cell stimulatory molecules, soluble CD23 (sCD23) and interleukin 6 (IL6), in the serum of HIV-infected individuals prior to the diagnosis of lymphoma. Serum sCD23 was elevated in those subjects who developed lymphoma, compared to AIDS, HIV+, and HIV- controls (P = 0.001). Serum IL6 was significantly elevated in subjects who developed Burkitt's/small noncleaved cell lymphoma (BL/SNC, P = 0.01), but not in those subjects who developed large cell, immunoblastic, or central nervous system lymphomas, compared to CD4-matched AIDS controls who did not have lymphoma. These results suggest that lymphomagenesis of the BL/SNC subtype of AIDS lymphoma reflects B cell hyperactivation of a different nature from that which precedes other subtypes of AIDS-associated B cell lymphoma. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479534     DOI: 10.1006/clim.1999.4760

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  26 in total

1.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Authors:  Mark P Purdue; Qing Lan; Rachel Bagni; William G Hocking; Dalsu Baris; Douglas J Reding; Nathaniel Rothman
Journal:  Cancer Res       Date:  2011-06-01       Impact factor: 12.701

2.  Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.

Authors:  Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

3.  Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.

Authors:  Yian Gu; Roy E Shore; Alan A Arslan; Karen L Koenig; Mengling Liu; Sherif Ibrahim; Anna E Lokshin; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2010-04-07       Impact factor: 2.506

4.  Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.

Authors:  Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

Review 5.  Cancer biomarkers in HIV patients.

Authors:  Richard F Ambinder; Kishor Bhatia; Otoniel Martinez-Maza; Ronald Mitsuyasu
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

6.  HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.

Authors:  Chun Chao; Lanfang Xu; Donald I Abrams; William J Towner; Michael A Horberg; Wendy A Leyden; Michael J Silverberg
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

7.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

Review 8.  Combination antiretroviral therapy and cancer risk.

Authors:  Álvaro H Borges
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

9.  Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.

Authors:  Shehnaz K Hussain; Nancy A Hessol; Alexandra M Levine; Elizabeth Crabb Breen; Kathryn Anastos; Mardge Cohen; Gypsyamber D'Souza; Deborah R Gustafson; Sylvia Silver; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

10.  Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.

Authors:  Anneclaire J De Roos; Dana K Mirick; Kerstin L Edlefsen; Andrea Z LaCroix; Kenneth J Kopecky; Margaret M Madeleine; Larry Magpantay; Otoniel Martínez-Maza
Journal:  Cancer Res       Date:  2012-07-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.